Did not find any updates like I was hoping for, but I double checked the protocols between the US and the European CF/Pa studies. Guess what?!? The US trial (Phase III) is still 28 days on, 56 days off. That is why the US study was never launched. If the Euro study shows that 28 days on, 28 days off is safe and efficacious, there is no reason why the data would not be compelling to the FDA. Besides INSM will probably be able to submit a significant portion of the Extension Trial (28 on, 28 off) as supporting data.